Get started
Author

Dylan M. Glatt

Observed names: D.M. Glatt, Dylan Glatt, Dylan M Glatt, Glatt, Dylan, PhD Dylan M Glatt,
ORCID: 0000-0002-2567-4752
Observed ORCID: 0000-0002-2567-4752
OpenAlex ID: A5028472874
The Flipped Classroom: A Course Redesign to Foster Learning and Engagement in a Health Professions School
2013 · Jacqueline E. McLaughlin, Mary T. Roth, et al. · Academic Medicine · 1,273
PDF
Pharmacy Student Engagement, Performance, and Perception in a Flipped Satellite Classroom
2013 · Jacqueline E. McLaughlin, LaToya M. Griffin, et al. · American Journal of Pharmaceutical Education · 446
PDF
Immuno-PET imaging of tumor-infiltrating lymphocytes using zirconium-89 radiolabeled anti-CD3 antibody in immune-competent mice bearing syngeneic tumors
2018 · Denis R. Beckford Vera, Christof C. Smith, et al. · PLoS ONE · 102
PDF
The Interplay of Antigen Affinity, Internalization, and Pharmacokinetics on CD44-Positive Tumor Targeting of Monoclonal Antibodies
2016 · Dylan M. Glatt, Denis R. Beckford Vera, et al. · Molecular Pharmaceutics · 23
Neurotoxicity of an Hepatitis B Virus (HBV) Transcript Inhibitor in 13-Week Rat and Monkey Studies
2022 · April D Lake, Kevin Holsapple, et al. · Toxicological Sciences · 18
PDF
23ME-00610, a genetically informed, first-in-class antibody targeting CD200R1 to enhance antitumor T cell function
2023 · Jill Fenaux, Xin Fang, et al. · OncoImmunology · 17
PDF
Synthesis and Characterization of Cetuximab–Docetaxel and Panitumumab–Docetaxel Antibody–Drug Conjugates for EGFR-Overexpressing Cancer Therapy
2018 · Dylan M. Glatt, Denis R. Beckford Vera, et al. · Molecular Pharmaceutics · 16
First-in-Human Study of 23ME-00610, an Antagonistic Antibody for Genetically Validated CD200R1 Immune Checkpoint, in Participants with Advanced Solid Malignancies
2024 · Shivaani Kummar, Albiruni Abdul Razak, et al. · Cancer Research Communications · 7
PDF
Discovery of Hepatitis B Virus Surface Antigen Suppressor GS-8873
2024 · Darryl Kato, Regina Wai-Yan Choy, et al. · ACS Medicinal Chemistry Letters · 2
PDF
150P Phase I/IIa trial of CD200R1 inhibitor 23ME-00610: Exploratory analyses of tissue-based and genetic biomarkers
2024 · A.R. Abdul Razak, A. Naing, et al. · Annals of Oncology · 1
PDF
1706P Efficacy, safety and PKPD of 23ME-00610, a first-in-class anti-CD200R1 antibody, in patients with advanced or metastatic clear-cell renal cell carcinoma (ccRCC): Results from a multi-center multi-country phase I/IIa expansion cohort
2024 · J. Krystal, A.R. Khaki, et al. · Annals of Oncology · 1
PDF
Safety, efficacy, and PKPD of 23ME-00610, a first-in-class anti-CD200R1 antibody, in patients with advanced neuroendocrine cancers: Results from a multi-center multi-country phase 1/2a expansion cohort.
2024 · Drew W. Rasco, Albiruni Ryan Abdul Razak, et al. · Journal of Clinical Oncology · 1
PDF
Abstract CT174: First-in-class anti-CD200R1 antibody 23ME-00610 in patients with advanced solid malignancies: Phase 1 results
2023 · Shivaani Kummar, Albiruni ABDUL RAZAK, et al. · Cancer Research · 1
758 A phase 1 dose escalation and expansion study of the anti-CD200R1 antibody 23ME-00610 in patients with advanced solid malignancies
2022 · Drew Rasco, Albiruni Razak, et al. · Journal for ImmunoTherapy of Cancer · 1
PDF
Phase 1 Study of Paltusotine, a Novel Oral Once‑Daily, Nonpeptide Selective Somatostatin Receptor 2 Agonist, in Healthy Japanese Adults
2026 · Fumio Otsuka, Keiko Hanabara, et al. · Clinical Pharmacology in Drug Development
First-in-Human Study of a Novel Nonpeptide Drug Conjugate (CRN09682) in Patients With Somatostatin Receptor 2-Expressing Tumors
2026 · MD Daneng Li,, Al Hallak, MD, MS Mohammed Najeeb, et al. · Endocrine Abstracts
Figure S1 from First-in-Human Study of 23ME-00610, an Antagonistic Antibody for Genetically Validated CD200R1 Immune Checkpoint, in Participants with Advanced Solid Malignancies
2025 · Shivaani Kummar, Albiruni Abdul Razak, et al.
Table 2 from First-in-Human Study of 23ME-00610, an Antagonistic Antibody for Genetically Validated CD200R1 Immune Checkpoint, in Participants with Advanced Solid Malignancies
2025 · Shivaani Kummar, Albiruni Abdul Razak, et al.
Figure S3 from First-in-Human Study of 23ME-00610, an Antagonistic Antibody for Genetically Validated CD200R1 Immune Checkpoint, in Participants with Advanced Solid Malignancies
2025 · Shivaani Kummar, Albiruni Abdul Razak, et al.
Supplementary Data from First-in-Human Study of 23ME-00610, an Antagonistic Antibody for Genetically Validated CD200R1 Immune Checkpoint, in Participants with Advanced Solid Malignancies
2025 · Shivaani Kummar, Albiruni Abdul Razak, et al.
Figure S2 from First-in-Human Study of 23ME-00610, an Antagonistic Antibody for Genetically Validated CD200R1 Immune Checkpoint, in Participants with Advanced Solid Malignancies
2025 · Shivaani Kummar, Albiruni Abdul Razak, et al.
Figure 2 from First-in-Human Study of 23ME-00610, an Antagonistic Antibody for Genetically Validated CD200R1 Immune Checkpoint, in Participants with Advanced Solid Malignancies
2025 · Shivaani Kummar, Albiruni Abdul Razak, et al.
Data from First-in-Human Study of 23ME-00610, an Antagonistic Antibody for Genetically Validated CD200R1 Immune Checkpoint, in Participants with Advanced Solid Malignancies
2025 · Shivaani Kummar, Albiruni Abdul Razak, et al.
Figure 3 from First-in-Human Study of 23ME-00610, an Antagonistic Antibody for Genetically Validated CD200R1 Immune Checkpoint, in Participants with Advanced Solid Malignancies
2025 · Shivaani Kummar, Albiruni Abdul Razak, et al.
Figure S4 from First-in-Human Study of 23ME-00610, an Antagonistic Antibody for Genetically Validated CD200R1 Immune Checkpoint, in Participants with Advanced Solid Malignancies
2025 · Shivaani Kummar, Albiruni Abdul Razak, et al.
Works count: 35
Citation count: 1,909
H-index: 7
I10-index: 7
Year
Topic
Type